Business Context and Reporting Period
Company: Processa Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 21, 2023
Reporting Period: Single event date (June 21, 2023)
This filing discloses a regulatory event regarding an upcoming investor presentation by Dr. David Young, Chief Executive Officer, at the MedInvest Oncology Investor Conference in Boston, MA.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding a corporate event and does not contain financial statements or performance data.
Material Changes
No material changes to financial position or operations are reported in this filing. The document solely announces a scheduled presentation event.
Guidance, Outlook, and Management Commentary
- Event: Dr. David Young will present on June 21, 2023, at 12:00 PM ET.
- Topic: "Next Generation Chemotherapy to Improve Treatment of Cancer while Treating More Patients."
- Availability: The presentation is furnished as Exhibit 99.1 and will be available on the company's website under the "Investors" section.
- Forward-Looking Statements: The company undertakes no duty to update or revise the information contained in this report or the presentation, except as required by law or through other public disclosures.
Investor Verification Checklist
- Verify the content of the presentation (Exhibit 99.1) for specific clinical data or strategic updates not detailed in the 8-K summary.
- Confirm the presentation is accessible via the company's official website investor relations portal.
- Note that the information in the presentation is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.